Scarica l'app Stockscreener
46.60
8.56%
-4.36
Pre-mercato:
46.80
0.20
+0.43%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTCT Giù?
Forum
Previsione
Precedente Chiudi:
$50.96
Aprire:
$50.73
Volume 24 ore:
2.88M
Relative Volume:
3.99
Capitalizzazione di mercato:
$3.33B
Reddito:
$900.66M
Utile/perdita netta:
$-453.20M
Rapporto P/E:
-7.8451
EPS:
-5.94
Flusso di cassa netto:
$-274.19M
1 W Prestazione:
-17.19%
1M Prestazione:
-15.67%
6M Prestazione:
+29.26%
1 anno Prestazione:
+62.99%
Intervallo 1D:
$46.37
$51.43
Intervallo di 1 settimana:
$45.40
$56.20
Portata 52W:
$24.00
$58.38
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Nome
Ptc Therapeutics Inc
Settore
Industria
Telefono
(908) 222-7000
Indirizzo
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Confronta PTCT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
46.60 | 3.33B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-11 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Iniziato | Scotiabank | Sector Perform |
| 2024-12-13 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-09-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-08-26 | Ripresa | UBS | Buy |
| 2024-05-20 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-10-30 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Downgrade | Citigroup | Neutral → Sell |
| 2023-10-06 | Downgrade | Truist | Buy → Hold |
| 2023-09-18 | Downgrade | Citigroup | Buy → Neutral |
| 2023-09-15 | Downgrade | Raymond James | Outperform → Underperform |
| 2023-03-17 | Iniziato | SVB Securities | Market Perform |
| 2022-12-14 | Iniziato | Goldman | Sell |
| 2022-09-12 | Iniziato | Jefferies | Buy |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2022-04-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-03-29 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-11-30 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-10-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-04-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-02-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-05-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Iniziato | Bernstein | Outperform |
| 2018-10-03 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-06-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Downgrade | JP Morgan | Neutral → Underweight |
Mostra tutto
Ptc Therapeutics Inc Borsa (PTCT) Ultime notizie
(PTCT) Technical Data - news.stocktradersdaily.com
PTC Therapeutics (NASDAQ:PTCT) Trading Down 8.8% Following Analyst Downgrade - MarketBeat
JPMorgan Chase & Co. Lowers PTC Therapeutics (NASDAQ:PTCT) Price Target to $75.00 - MarketBeat
Pictet Asset Management Holding SA Has $33.24 Million Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Raymond James Financial Inc. Makes New $2.20 Million Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
Natixis Advisors LLC Invests $544,000 in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics says Duchenne drug Translarna is no longer authorized in EU - MSN
Cibc World Markets Corp Acquires Shares of 7,127 PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StreetInsider.com
PTC Therapeutics Faces EU Setback on Translarna - TipRanks
PTC Therapeutics says EC will not renew market authorization for muscle disorder drug - MarketScreener
PTC Therapeutics stock slips as EU ends Translarna nod (PTCT) - Seeking Alpha
PTC Therapeutics faces EC setback on Translarna in Europe - Investing.com
PTC Therapeutics (PTCT) Faces EU Setback for DMD Drug Translarna - GuruFocus
European Commission Declines To Renew Marketing Authorization Of Translarna Duchenne Muscular Disorder - Benzinga
PTC Therapeutics says EC not to renew market authorization for muscle disorder drug - MarketScreener
PTC Therapeutics Provides Regulatory Update on Translarna™ (ataluren) in Europe - Quantisnow
PTC Therapeutics Loses EU Authorization for Translarna in Duchenne Muscular Dystrophy - MarketScreener
PTC Therapeutics: European Commission Decides To Adopt CHMP Negative Opinion On Translarna - Nasdaq
PTC Therapeutics says European Commission will remove muscle disorder drug - MarketScreener
PTC Therapeutics Provides Regulatory Update On Translarna(TM) (Ataluren) In Europe - Marketscreener.com
PTC Therapeutics faces EC setback on Translarna in Europe By Investing.com - Investing.com Australia
Sector Gamma AS Purchases Shares of 65,250 PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
A Shareholder alert for PTC Therapeutics, Inc was sent by Bronstein, Gewirtz and Grossman, LLC to Lead Class Action Lawsuit! - ACCESS Newswire
AlphaQuest LLC Has $49,000 Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Sets New 52-Week HighShould You Buy? - MarketBeat
First Week of May 16th Options Trading For PTC Therapeutics - Nasdaq
Leigh Syndrome Treatment Market Size in 7MM is expected to grow - openPR
Connor Clark & Lunn Investment Management Ltd. Sells 15,278 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Proficio Capital Partners LLC Takes $758,000 Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Stephanie Okey Sells 5,000 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock - MarketBeat
Insider Sell Alert: Eric Pauwels Sells Shares of PTC Therapeutics Inc (PTCT) - GuruFocus
Charles Schwab Investment Management Inc. Trims Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics reports progress in PKU treatment study By Investing.com - Investing.com Australia
PTC Therapeutics Reveals New Sepiapterin Data From Phase 3 Study In Patients With Inherited Disorder, FDA Decision Expected In July - Benzinga
PTC Therapeutics reports progress in PKU treatment study - Investing.com India
PTCT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that PTC Therapeutics, Inc Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
JPMorgan Chase & Co. Boosts PTC Therapeutics (NASDAQ:PTCT) Price Target to $78.00 - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Hits New 12-Month High After Analyst Upgrade - MarketBeat
PTC Therapeutics chief business officer sells $630,104 in stock - Investing.com India
PTC Therapeutics chief business officer sells $630,104 in stock By Investing.com - Investing.com UK
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Mark Elliott Boulding Sells 15,521 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock - MarketBeat
Director Okey Stephanie sold $270,000 worth of shares (5,000 units at $54.00), decreasing direct ownership by 36% to 8,867 units (SEC Form 4) - Quantisnow
PTCT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that PTC Therapeutics, Inc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Ptc Therapeutics Inc Azioni (PTCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.89%
0.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):